-
Mashup Score: 58Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial - PubMed - 4 month(s) ago
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Gemcitabine + oxaliplatin (GemOx) with rituximab, a standard salvage therapy, yields complete response (CR) rates of approximately 30% and median overall survival (OS) of 10-13 months. Patients with …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies - 6 month(s) ago
Key Points. Three-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies showed long-lasting remissions and meaningful survival outcomesManagea
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
📢 New in @BloodJournal: 3-year F/U of Phase 1/2 mosunetuzumab in heavily pretreated r/r follicular lymphoma patients: 43.2% remain progression-free at 36 months. Is this a plateau? https://t.co/nZXWkPlwUY https://t.co/jHJJj9T9sV
-
-
Mashup Score: 3Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies - 6 month(s) ago
Key Points. Three-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies showed long-lasting remissions and meaningful survival outcomesManagea
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
📢 New in @BloodJournal: 3-year F/U of Phase 1/2 mosunetuzumab in heavily pretreated r/r follicular lymphoma patients: 43.2% remain progression-free at 36 months. Is this a plateau? https://t.co/nZXWkPlwUY https://t.co/jHJJj9T9sV
-
-
Mashup Score: 3Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies - 6 month(s) ago
Key Points. Three-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies showed long-lasting remissions and meaningful survival outcomesManagea
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
📢 New in @BloodJournal: 3-year F/U of Phase 1/2 mosunetuzumab in heavily pretreated r/r follicular lymphoma patients: 43.2% remain progression-free at 36 months. Is this a plateau? https://t.co/nZXWkPlwUY https://t.co/jHJJj9T9sV
-
-
Mashup Score: 0Happy 97th Birthday, Herbert Blomstedt ! - 10 month(s) ago
Happy 97th birthday, dearest Maestro Herbert Blomstedt! 💐🎉🎵On July 11, 2024, Herbert Blomstedt celebrated his 97th birthday. A little bird told the @Bambe…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
Happy 97th Birthday, Herbert Blomstedt ! https://t.co/d8p97BRgp8
-
-
Mashup Score: 0
Die Kontroverse um die Ernennung von Damian Müller zum Präsidenten des Verwaltungsrates der Luks Gruppe hat diesen am Samstag dazu veranlasst, auf das Amt zu verzichten.
Source: www.luzernerzeitung.chCategories: General Medicine News, Hem/OncsTweet-
Anybody talked to Prof Verena Briner? @KantonsspitalLU @mtschuor3 She already lead @Novartis successfully. Time for a woman as VR President. https://t.co/6C8lq2uFlw
-
-
Mashup Score: 2
A study published by Public Health Scotland finds that the HPV vaccine is “highly effective”.
Source: www.bbc.comCategories: General Medicine News, Hem/OncsTweet-
It’s almost as if vaccines work, who’d have thought? Science is the best. https://t.co/ipEUPoBW4T
-
-
Mashup Score: 2
A study published by Public Health Scotland finds that the HPV vaccine is “highly effective”.
Source: www.bbc.comCategories: General Medicine News, Hem/OncsTweet-
It’s almost as if vaccines work, who’d have thought? Science is the best. https://t.co/ipEUPoBW4T
-
-
Mashup Score: 0Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial - 1 year(s) ago
Leukemia – Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
@AaronGoodman33 If you consider a lower pomalidomide dose, think of giving 4mg every second day. It works well. https://t.co/RGqOsBMEOt
-
-
Mashup Score: 0Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial - 2 year(s) ago
Leukemia – Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
@VincentRK Pom 4mg every second day is a valid and clever alternative: https://t.co/RGqOsBM6YV
-
Epcoritamab + GemOx yielded deep, durable responses and favorable long-term outcomes in ASCT‑ineligible R/R #DLBCL. I really like these BiTE/Chemo combinations. Is someone challenging CART in a randomized trial? @graham74GC https://t.co/GydTmhXzUX https://t.co/1PffsBxD05